Cargando…

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

OBJECTIVE: To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of mavrilimumab, a human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, in subjects with rheumatoid arthritis (RA). METHODS: A randomised, double-blind, place...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Feist, Eugen, Sleeman, Matthew A, Wang, Bing, White, Barbara, Magrini, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147227/
https://www.ncbi.nlm.nih.gov/pubmed/21613310
http://dx.doi.org/10.1136/ard.2010.146225
_version_ 1782209307756986368
author Burmester, Gerd R
Feist, Eugen
Sleeman, Matthew A
Wang, Bing
White, Barbara
Magrini, Fabio
author_facet Burmester, Gerd R
Feist, Eugen
Sleeman, Matthew A
Wang, Bing
White, Barbara
Magrini, Fabio
author_sort Burmester, Gerd R
collection PubMed
description OBJECTIVE: To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of mavrilimumab, a human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, in subjects with rheumatoid arthritis (RA). METHODS: A randomised, double-blind, placebo-controlled, dose-escalating phase I study in subjects with RA who received stable methotrexate treatment for ≥3 months before enrolment. Subjects received single intravenous escalating doses of mavrilimumab (0.01–10.0 mg/kg) or placebo. RESULTS: 32 subjects were enrolled in this study (1 unblinded subject at 0.01 mg/kg and another at 0.03 mg/kg were followed by five sequential double-blinded cohorts, n=6 each, treated with 0.1, 0.3, 1.0, 3.0 and 10.0 mg/kg, respectively). Adverse events were mild or moderate and were reported with similar frequency across all treatment cohorts. One subject (10.0 mg/kg) experienced moderate face and neck urticaria during infusion that resolved with symptomatic treatment. Systemic clearance of mavrilimumab approached that of endogenous IgG at doses >1.0 mg/kg; pharmacodynamic activity was confirmed in the 1.0 and 3.0 mg/kg cohorts by suppression of suppressor of cytokine signalling 3 mRNA transcripts. In exploratory analyses, reductions of acute phase reactants were observed in subjects with elevated C-reactive protein (>5 mg/l) and erythrocyte sedimentation rate (≥20.0 mm/h) at baseline. No significant change in Disease Activity Score 28-joint assessment (DAS28) was seen in any of the cohorts. In mavrilimumab-treated subjects (n=15) with baseline DAS28 >3.2, mean disease activity (DAS28) was significantly reduced at 4 weeks. CONCLUSION: In this first-in-human study, mavrilimumab showed preliminary evidence of pharmacodynamic activity. Importantly, the safety and pharmacokinetic profiles of mavrilimumab support further clinical studies in RA. Trial registration number: NCT00771420.
format Online
Article
Text
id pubmed-3147227
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-31472272011-08-15 Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study Burmester, Gerd R Feist, Eugen Sleeman, Matthew A Wang, Bing White, Barbara Magrini, Fabio Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVE: To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of mavrilimumab, a human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, in subjects with rheumatoid arthritis (RA). METHODS: A randomised, double-blind, placebo-controlled, dose-escalating phase I study in subjects with RA who received stable methotrexate treatment for ≥3 months before enrolment. Subjects received single intravenous escalating doses of mavrilimumab (0.01–10.0 mg/kg) or placebo. RESULTS: 32 subjects were enrolled in this study (1 unblinded subject at 0.01 mg/kg and another at 0.03 mg/kg were followed by five sequential double-blinded cohorts, n=6 each, treated with 0.1, 0.3, 1.0, 3.0 and 10.0 mg/kg, respectively). Adverse events were mild or moderate and were reported with similar frequency across all treatment cohorts. One subject (10.0 mg/kg) experienced moderate face and neck urticaria during infusion that resolved with symptomatic treatment. Systemic clearance of mavrilimumab approached that of endogenous IgG at doses >1.0 mg/kg; pharmacodynamic activity was confirmed in the 1.0 and 3.0 mg/kg cohorts by suppression of suppressor of cytokine signalling 3 mRNA transcripts. In exploratory analyses, reductions of acute phase reactants were observed in subjects with elevated C-reactive protein (>5 mg/l) and erythrocyte sedimentation rate (≥20.0 mm/h) at baseline. No significant change in Disease Activity Score 28-joint assessment (DAS28) was seen in any of the cohorts. In mavrilimumab-treated subjects (n=15) with baseline DAS28 >3.2, mean disease activity (DAS28) was significantly reduced at 4 weeks. CONCLUSION: In this first-in-human study, mavrilimumab showed preliminary evidence of pharmacodynamic activity. Importantly, the safety and pharmacokinetic profiles of mavrilimumab support further clinical studies in RA. Trial registration number: NCT00771420. BMJ Group 2011-05-25 /pmc/articles/PMC3147227/ /pubmed/21613310 http://dx.doi.org/10.1136/ard.2010.146225 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Clinical and Epidemiological Research
Burmester, Gerd R
Feist, Eugen
Sleeman, Matthew A
Wang, Bing
White, Barbara
Magrini, Fabio
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
title Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
title_full Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
title_fullStr Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
title_full_unstemmed Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
title_short Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
title_sort mavrilimumab, a human monoclonal antibody targeting gm-csf receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase i, first-in-human study
topic Clinical and Epidemiological Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147227/
https://www.ncbi.nlm.nih.gov/pubmed/21613310
http://dx.doi.org/10.1136/ard.2010.146225
work_keys_str_mv AT burmestergerdr mavrilimumabahumanmonoclonalantibodytargetinggmcsfreceptorainsubjectswithrheumatoidarthritisarandomiseddoubleblindplacebocontrolledphaseifirstinhumanstudy
AT feisteugen mavrilimumabahumanmonoclonalantibodytargetinggmcsfreceptorainsubjectswithrheumatoidarthritisarandomiseddoubleblindplacebocontrolledphaseifirstinhumanstudy
AT sleemanmatthewa mavrilimumabahumanmonoclonalantibodytargetinggmcsfreceptorainsubjectswithrheumatoidarthritisarandomiseddoubleblindplacebocontrolledphaseifirstinhumanstudy
AT wangbing mavrilimumabahumanmonoclonalantibodytargetinggmcsfreceptorainsubjectswithrheumatoidarthritisarandomiseddoubleblindplacebocontrolledphaseifirstinhumanstudy
AT whitebarbara mavrilimumabahumanmonoclonalantibodytargetinggmcsfreceptorainsubjectswithrheumatoidarthritisarandomiseddoubleblindplacebocontrolledphaseifirstinhumanstudy
AT magrinifabio mavrilimumabahumanmonoclonalantibodytargetinggmcsfreceptorainsubjectswithrheumatoidarthritisarandomiseddoubleblindplacebocontrolledphaseifirstinhumanstudy